Form 4: STERIS CEO Sells Shares Under 10b5-1 Plan

STERIS plc President and CEO Daniel A. Carestio sold 159 ordinary shares for $241.82 each, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Daniel A. Carestio, President and CEO of STERIS plc, sold 159 ordinary shares.
• The transaction occurred on October 6, 2025, at a price of $241.82 per share.
• The sale was conducted under a Rule 10b5-1(c) trading plan, indicating it was pre-scheduled.
• Following the transaction, Carestio beneficially owns 51,096 ordinary shares.
• Of the beneficially owned shares, 33,054 are restricted, with vesting schedules extending from June 2026 to June 2028.

Sentiment

Score: 5

Explanation: A neutral score as the transaction is a routine insider sale under a pre-arranged 10b5-1 plan, which typically does not indicate a strong positive or negative sentiment about the company's future prospects. The amount is also relatively small.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-scheduled sale rather than a reaction to immediate market conditions, which can reduce concerns about opportunistic insider selling.

Negatives

• A sale of shares by a CEO, even if pre-planned, reduces their direct equity stake in the company, which some investors might view as a slight reduction in alignment of interests.

Future Outlook

NA

Industry Context

This Form 4 filing reports an insider transaction for STERIS plc, a company operating in the healthcare products and services industry. Insider sales, even under 10b5-1 plans, are routinely monitored by investors for insights into management's perspective on company valuation, though a small sale like this is unlikely to signal a significant shift in industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minor impact due to a small, pre-planned sale by the CEO. The sale itself is not indicative of a change in company fundamentals.

Key Dates

Recommendation

The filing reports a routine, pre-scheduled insider sale by the CEO under a 10b5-1 plan. The number of shares sold is relatively small compared to the CEO's total holdings and the company's market capitalization. This type of transaction typically does not provide new fundamental information to warrant a change in investment thesis, hence a 'hold' recommendation is appropriate, maintaining existing positions based on broader company performance and market conditions.

Keywords

STERIS plc, STE, Daniel A. Carestio, Insider Trading, Form 4, Share Sale, CEO, 10b5-1 Plan, Restricted Stock